Mission and Vision

The VIB-UGent Center for Medical Biotechnology (CMB) is VIB’s main center of biomolecular analytics and biopharmaceutical engineering research, with a key focus on protein technology.

CMB researchers operate within the Center’s overall vision of innovating the analysis and engineering of biomolecular systems to investigate and alleviate human disease.

CMB’s strategic approach is technological innovation-driven, inspired by solving selected biomedical research, diagnostics and therapeutic challenges for which we believe that our particular technological innovations could have the largest impact.

CMB’s mission is to push the boundaries of protein-focused biomolecular and bioinformatics research and engineering technologies, to translate our novel technologies and insights to widely applicable research tools, vaccines, diagnostics and biopharmaceuticals, to educate and train the next generation of medical biotechnology researchers and to inform the public on the impact of biotechnology on human health.

Beyond borders

CMB is active within VIB and Ghent University. A strong incentive to bring CMB technologies to patients resulted in the creation of five spin-off companies; Devgen (acquired by Syngenta), Pronota (acquired by MyCartis), Oxyrane, Orionis Biosciences and ExeVir Bio.

Funding and partners

CMB research is supported by Ghent University, the Flemish government and many (inter)national funding bodies.

Center address

VIB-UGent for Medical Biotechnology
UGent-VIB Research Building FSVMII 
Technologiepark - Zwijnaarde 75
9052 Ghent

Science Director: Nico Callewaert